The typical case for the fund is to invest in rounds with 10 participants. The meaningful sponsors for the fund in investment in the same round are T. Rowe Price, Sigma Capital Group, Rosewood Corporation. In the next rounds fund is usually obtained by AstraZeneca.
We can highlight the next thriving fund investment areas, such as Biopharma, Therapeutics. Besides, a startup needs to be aged 11-15 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline FibroGen
The increased amount of exits for fund were in 2014. The common things for fund are deals in the range of more than 100 millions dollars. The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2005.
| Fund Name | Location |
| Anhui Provincial Emerging Industry Investment | Anhui, China, Hefei |
| Brightbridge Ventures | England, London, United Kingdom |
| Fierce Capital | Andalucia, Málaga, Spain |
| Flightpath Ventures | California, San Francisco, United States |
| Fond fondov | District of Zvolen, Region of Banská Bystrica, Slovakia |
| Guidepost Growth Equity | Boston, Massachusetts, United States |
| Inspire Growth Wales | Cardiff, United Kingdom, Wales |
| IRPC Public Company | Bangkok, Krung Thep, Thailand |
| Key Venture Partners | Boston, Massachusetts, United States |
| Modernization and Technology Development Fund | - |
| New Investment Solutions | Liechtenstein, Oberland, Vaduz |
| Nomadic Japan | Chiyoda, Japan |
| Other Corporate Investors | - |
| Prudential Capital Partners | Chicago, Illinois, United States |
| redpartners gmbh | - |
| Stitch Fix | California, San Francisco, United States |
| Texas Investment Network | Dallas, Texas, United States |
| Transformational Healthcare Opportunity | - |
| YA Global Master SPV | Mountainside, New Jersey, United States |
| Zhongxing Hongtai Touzi | China, Shaanxi, Xian Shi |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data 